clinical trial · NCT07163364
A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·phase3·not yet recruiting·n = 20
Methylmalonic Acidemia (MMA)Hydroxocobalamin Chloride Injection
brief summary
This study is a Single-Center, Single-Arm, open-label, Phase III clinical study to evaluate the efficacy, safety characteristics of Hydroxocobalamin Chloride Injection (20 mg/mL) for Maintenance Therapy in participants with Methylmalonic Acidemia (MMA) with Elevated Homocysteine (Cobalamin C Deficiency).
started
Aug 31, 2025
primary completion
Oct 8, 2026
completion
Apr 28, 2027
last updated
Sep 9, 2025
official title
A Single-arm Phase III Clinical Study to Evaluate the Efficacy and Safety of Hydroxocobalamin Chloride Injection in Participants With Methylmalonic Acidemia (MMA) With Elevated Homocysteine (Cobalamin C Deficiency)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol